Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 Next >
Bayer and Luke Bryan Reunite for Annual #HerestotheFarmer Campaign in Support of Feeding America and Rural Communities
From Bayer
Via Business Wire
Bayer initiates Phase III studies with investigational contrast agent gadoquatrane
From Bayer
Via Business Wire
FDA approves Bayer’s Ultravist® (iopromide) injection for contrast-enhanced mammography
From Bayer
Via Business Wire
Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes
From Bayer
Via Business Wire
Bayer Announces Senior Bayer Representative and President of Bayer U.S.
From Bayer
Via Business Wire
Bayer Announces Changes to U.S. Country Leadership Team
From Bayer
Via Business Wire
Bayer Strengthens Gene Therapy Portfolio With Lipid Nanoparticle Technology From Acuitas Therapeutics
From Bayer
Via Business Wire
Latest Vitrakvi® (larotrectinib) Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy and Safety Profile in Adult and Pediatric Patients with NTRK Gene Fusion Cancer, Across Solid Tumors
From Bayer
Via Business Wire
Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in pre-clinical precision oncology
From Bayer
Via Business Wire
Bayer Launches Unit to Develop New Precision Health Consumer Products
From Bayer
Via Business Wire
Bayer Presents New Data Across Oncology Portfolio at the 2023 ASCO Annual Meeting
From Bayer
Via Business Wire
Bayer launches Seeing Red campaign around the treatment of Heavy Menstrual Bleeding (HMB)
From Bayer
Via Business Wire
Bayer Receives U.S. FDA Fast Track Designation for asundexian Atrial Fibrillation Program
From Bayer
Via Business Wire
Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by Leaps by Bayer and RA Capital Management to Advance the First ecDNA-Directed Therapies (ecDTx) for Patients with Oncogene Amplified Cancer
From Bayer
Via Business Wire
Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology
From Bayer
Via Business Wire
Tickers BCYC
Bayer Opens First Co.Lab Life Science Incubator in Cambridge
From Bayer
Via Business Wire
Bayer Announces New Strategic Collaboration with New Jersey’s Leading Polytechnic Universities to Cultivate Data Science Talent in Region
From Bayer
Via Business Wire
There Is No Room for Allergy Fog This Spring Allergy Season with Claritin®
From Bayer
Via Business Wire
Claritin® Takes Aim at Reducing Pollen Levels Through Female Tree Planting Initiative
From Bayer
Via Business Wire
Astepro® Allergy Partners with Meghann Fahy to Help Allergy Sufferers Conquer Allergies, Love & Spontaneity Fast
From Bayer
Via Business Wire
Bayer Expands Global Clinical Program for NUBEQA® (darolutamide) in Prostate Cancer
From Bayer
Via Business Wire
UN 2023 Water Conference: Bayer pledges to help tackle global water crisis with new water strategy
From Bayer
Via Business Wire
Bayer collaborates with Microsoft to unveil new cloud-based enterprise solutions, advancing innovation and transparency in the agri-food industry
From Bayer
Via Business Wire
Bayer US Joins the Fight to Combat Water Crisis
From Bayer
Via Business Wire
World Kidney Day: A Bayer Survey Reveals Physicians Agree on Need for Earlier Testing and Increased Transparent Communication for People Diagnosed With Chronic Kidney Disease Associated With Type 2 Diabetes
From Bayer
Via Business Wire
Bayer Unveils the Preceon™ Smart Corn System, Transforming How Farmers Manage Their Corn Crop
From Bayer
Via Business Wire
Bayer Expands its “Nutrient Gap Initiative” to Help End Malnutrition
From Bayer
Via Business Wire
New NUBEQA® (darolutamide) Subgroup Analyses from the Phase III ARASENS Trial in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Patients Presented at ASCO GU
From Bayer
Via Business Wire
Bill Anderson to Become CEO of Bayer AG
From Bayer
Via Business Wire
Bayer Announces First Patients Enrolled in Global Phase III Studies for Investigational Oral FXIa Inhibitor Asundexian
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.